Drug Discovery Stories, Volume 3
From Bench to Bedside
- 1st Edition - March 1, 2027
- Latest edition
- Editor: Bin Yu
- Language: English
Drug Discovery Stories: From Bench to Bedside, Volume 3 presents a collection of cases on the development of highly successful pharmaceuticals. The coverage of chapters in the bo… Read more
Description
Description
Drug Discovery Stories: From Bench to Bedside, Volume 3 presents a collection of cases on the development of highly successful pharmaceuticals. The coverage of chapters in the book include the structural biology and biological functions of the targets of interest, the identification of hit compounds, hit-to-lead optimization, binding mode of the key compounds with the target of interest, key biological and PK data of lead compounds, clinical results if any, other candidate compounds in preclinical and clinical stage against the same target, and other relevant points in the journey to develop the drug. Chapters in this volume in the Drug Discovery Stories series include a discussion of technological innovations in drug discovery, the impact of AI and Machine Learning, and then move on to discuss drugs like Landiolol, Deuruxolitinib, Berdazimer sodium, Cefepime, Aprocitentan, Givinostat, Vadadustat, Danicopan, Tovorafenib, Lazertinib, Journavx, Symbravo, Grafapex, Alyftrek, and Tryngolza. A final chapter provide conclusions on all cases presented in the book. Drug Discovery Stories: From Bench to Bedside, Volume 3 accurately reflects the current advancements in drug discovery by sharing the path researchers took that led them to create these impactful drugs. This book aims to not only cater to the drug discovery community but also engage other communities involved in chemical biology, synthetic chemistry, and pharmacology.
Key features
Key features
- Describes the drug discovery stories of different blockbuster drugs
- Provides insights into the drug discovery journey for the specific drugs presented
- Covers recently approved drugs of great therapeutic potential
Readership
Readership
Drug discovery researchers in industry and academia
Table of contents
Table of contents
1. Evolution of drug discovery and the impact of technological innovations
2. AI in drug discovery for novel therapeutics
3. Landiolol: pharmacology and its use for rate control in atrial fibrillation in an emergency setting
4. Deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata
5. Berdazimer sodium (Zelsuvmi), a medication used for the treatment for molluscum contagiosum
6. Cefepime/Enmetazobactam: a microbiological, pharmacokinetic, pharmacodynamic, and clinical evaluation
7. Aprocitentan, a Newly Approved Drug for Resistant Hypertension
8. Givinostat (Duvyzat), a potential treatment for Duchenne muscular dystrophy
9. Vadadustat, an orally administered inhibitor of HIF-PH with a safety and efficacy profile for the treatment of anemia in patients with CKD
10. Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria
11. Tovorafenib, an oral, brain-penetrant, highly-selective type II RAF kinase inhibitor
12. Lazertinib, a tyrosine kinase inhibitor used in combination with amivantamab to treat non-small cell lung cancer with EGFR mutations
13. Journavx (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
14. Symbravo (meloxicam and rizatriptan), a non-steroidal anti-inflammatory drug for the Acute Treatment of Migraine with or without Aura in Adults
15. Grafapex (treosulfan), an alkylating agent for Allogeneic Hematopoietic Stem Cell Transplantation
16. Alyftrek, a next-in-class, triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis
17. Tryngolza (olezarsen), an apoC-III-directed antisense oligonucleotide to reduce triglycerides in adults with familial chylomicronemia syndrome
18. Prospective analysis of approved drugs
2. AI in drug discovery for novel therapeutics
3. Landiolol: pharmacology and its use for rate control in atrial fibrillation in an emergency setting
4. Deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata
5. Berdazimer sodium (Zelsuvmi), a medication used for the treatment for molluscum contagiosum
6. Cefepime/Enmetazobactam: a microbiological, pharmacokinetic, pharmacodynamic, and clinical evaluation
7. Aprocitentan, a Newly Approved Drug for Resistant Hypertension
8. Givinostat (Duvyzat), a potential treatment for Duchenne muscular dystrophy
9. Vadadustat, an orally administered inhibitor of HIF-PH with a safety and efficacy profile for the treatment of anemia in patients with CKD
10. Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria
11. Tovorafenib, an oral, brain-penetrant, highly-selective type II RAF kinase inhibitor
12. Lazertinib, a tyrosine kinase inhibitor used in combination with amivantamab to treat non-small cell lung cancer with EGFR mutations
13. Journavx (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
14. Symbravo (meloxicam and rizatriptan), a non-steroidal anti-inflammatory drug for the Acute Treatment of Migraine with or without Aura in Adults
15. Grafapex (treosulfan), an alkylating agent for Allogeneic Hematopoietic Stem Cell Transplantation
16. Alyftrek, a next-in-class, triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis
17. Tryngolza (olezarsen), an apoC-III-directed antisense oligonucleotide to reduce triglycerides in adults with familial chylomicronemia syndrome
18. Prospective analysis of approved drugs
Product details
Product details
- Edition: 1
- Latest edition
- Published: March 1, 2027
- Language: English
About the editor
About the editor
BY
Bin Yu
Professor Bin Yu obtained his PhD degree from Zhengzhou University and University of Cambridge and currently is a professor of medicinal chemistry at School of Pharmaceutical Sciences, Zhengzhou University. His research interests focus on chemistry driven drug discovery for novel therapeutics. To date, he has published over 120 papers in international high-impact peer-reviewed journals including Journal of Medicinal Chemistry, Organic Letters, Pharmacology & Therapeutics, Journal of Hematology & Oncology, Drug Discovery Today, Acta Pharmaceutica Sinica B, etc., 10 of them were published in journal with impact factor (IF) >10.
Affiliations and expertise
Professor of Medicinal Chemistry, School of Pharmaceutical Sciences, Zhengzhou University, China